cyrilzakka/clinical-trials huggingface dataset:
C677T Methylenetetrahydrofolate Reductase Mutation

To investigate the effect of anticoagulant treatment on pregnancy outcomes in patients with previous recurrent miscarriages (RM) who carry a methylenetetrahydrofolate reductase (MTHFR) gene mutation.

In this longitudinal retrospective study, patients with RM were treated during pregnancy with either: (i) 100 mg/day aspirin and 5 mg/day folic acid (group 1); or the same protocol plus 0.4 mg/day enoxaparin (group 2). An age-matched group of triparous women without RM or thrombophilia was used as the control group (group 3).

Recurrent miscarriage (RM) is defined as three or more consecutive spontaneous fetal losses and it affects 0.3% to 1% of pregnancies.To investigate the effect of anticoagulant treatment on pregnancy outcomes in patients with previous recurrent miscarriages (RM) who carry a methylenetetrahydrofolate reductase (MTHFR) gene mutation.

In this longitudinal retrospective study, patients with RM were treated during pregnancy with either: (i) 100 mg/day aspirin and 5 mg/day folic acid (group 1); or the same protocol plus 0.4 mg/day enoxaparin (group 2). An age-matched group of triparous women without RM or thrombophilia was used as the control group (group 3).

Eligibility Criteria:
Inclusion Criteria:

* patients with three or more consecutive first-trimester miscarriage
* Three or more consecutive first-trimester miscatrriages
* C677T MTHFR gene mutation

Exclusion Criteria:

* Patients with the A1298C polymorphism
Pain Management in Arthtroscopic Shoulder Surgery

It is compared that combined suprascapular and infraclavicular nerve blocks to interscalene nerve block for clinical outcomes after shoulder surgery

In this study, the investigators planned to investigate postoperative pain, analgesic dosage, respiratory effects of the block and side effects of patients undergoing general anaesthesia after arthroscopic shoulder surgery under preoperative interscalene nerve block or suprascapular + infraclavicular nerve block.

Eligibility Criteria:
Inclusion Criteria:

* Patients scheduled for elective shoulder surgery under general anesthesia with suprascapular + infraclavicular nerve block or interscalene nerve block for any reason ASA 1-3 patients

Exclusion Criteria:

* Diabetes
* coagulopathy
* local anesthetic allergy
* chronic opioid users
* neurological deficit of the surgical limb
* obstructive or restrictive pulmoner disease
* inability to understand pain scores
Patients With Type B Aortic Dissection Returning to Work After Discharge：a Cross-sectional Survey

This study wants to understand the incidence of returning to work after discharge in patients with type B aortic dissection.

The incidence of aortic dissection in China is increasing year by year. According to the latest research report, the annual incidence of aortic dissection in China is 5 \~ 10 / 100,000, the average age of patients is 51.8 years old, and the age of disease is about 10 years younger than that of European and American countries. RTW after discharge is a measure of disease recovery and recovery to normal state. There are only reports on RTW after discharge in the fields of cancer, stroke, organ transplantation, maintenance peritoneal dialysis and so on. Most of the existing literature in the cardiovascular field at home and abroad focuses on assessing the status of RTW and RRTW after discharge. Up to now, there is still a lack of research on the promotion and hindrance factors of RTW in TBAD patients, the status survey of post-RTW work ability and the related nomogram prediction model. Therefore, based on the Meleis transformation theory, this study aims to investigate the current status of return to work of TBAD patients at 6 months after discharge through quantitative and qualitative research, and to explore its influencing factors in depth. Based on the previous results, the RTW visual prediction model of TBAD patients was constructed, which provided a theoretical basis for the formulation and implementation of early intervention by medical staff, and further improved the research in this field.

Eligibility Criteria:
Inclusion Criteria:

( 1 ) TBAD was diagnosed by computed tomography angiography ( CTA ) or magnetic resonance angiography ( MRA ) ; ( 2 ) 18 years ≤ age \< 60 years at diagnosis ; ( 3 ) having full-time or part-time job at the time of diagnosis ; ( 4 ) TBAD patients were discharged after successful treatment and the discharge time was ≥ 6 months ;

Exclusion Criteria:

( 1 ) reaching the retirement age 6 months after discharge ; ( 2 ) those with disturbance of consciousness, mental illness, inability to complete the interview independently or under the guidance of the researcher ; ( 3 ) Participate in other related research ; ( 4 ) Clinical end-stage or receiving palliative treatment.
e-Counseling Promotes Blood Pressure Reduction and Therapeutic Lifestyle Change in Hypertension

This proposed clinical trial, REACH, will enroll 538 persons with hypertension. All subjects will continue with their prescribed medications. Our main objective is to assess whether preventive e-counseling (provided through a website of the Heart and Stroke Foundation) improves blood pressure and cardiovascular risk status over a 12-month interval. REACH will also evaluate improvement in lifestyle behaviors that include diet, exercise, smoking, and adherence to prescribed medications. Finally, we will quantify the amount of e-counseling support that is required during REACH to evoke a significant reduction in blood pressure. It is hypothesized that e-Counseling (vs. Control) will significantly improve blood pressure and lifestyle behaviours at the 12-month assessment. The findings of this trial will provide information that is critical to our understanding of how internet-based programs can help to improve blood pressure and to reduce the risk for cardiovascular disease.


Eligibility Criteria:
Inclusion Criteria:

* Age: 35-74 years
* Diagnosis of hypertension: Medication or physician confirmation
* Baseline BP in lab: \>=140/90 (if no meds); \>=130/85 (if on meds)
* If medications, prescription unchanged \>=2 months Comprehension of English (oral and written)

Exclusion Criteria:

* diagnosis of clinically significant arrhythmia, sleep apnea, kidney disease, major psychiatric illness (eg. psychosis), alcohol or drug dependence in the previous year; institutional residence, or an inability to comprehend English
Zenith® Low Profile AAA Endovascular Graft

This extended investigation is to provide continued physician access to the device and collect confirmatory safety and effectiveness data.


Eligibility Criteria:
Inclusion Criteria:

•Subject has at least one of the following

* Aortic or aortoiliac aneurysm
* Iliac aneurysm
* Aneurysm with a history of growth

Exclusion Criteria:

* Less than 18 years of age
* Inability or refusal to give informed consent
* Life expectancy less than 2 years
* Pregnant of breastfeeding or planning on becoming pregnant with 60 months
* Unwilling to comply with the follow-up schedule
A Multicenter Study to Evaluate the Nutritional Suitability of Renastart

A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD)

A multicenter, open label, uncontrolled study to evaluate the acceptability, tolerability, and nutritional suitability of a medical food (Renastart, Vitaflo International Ltd) specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD)

Primary Objective To investigate the nutritional suitability of Renastart in children aged 10 years and under with CKD, particularly with respect to the dietary management of hyperkalemia and the maintenance / improvement of growth.

Secondary Objectives To investigate the acceptance, compliance, palatability, and tolerance of Renastart in children aged under 10 years with CKD.

A total of 15 children with CKD will be enrolled in the study.

Eligibility Criteria:
Inclusion Criteria:

1. Aged 10 years or under at the time of enrolment into the study.
2. Diagnosed with Chronic Kidney Disease
3. Requirement for a low potassium diet, as evidence by elevated serum potassium levels (\> normal reference value which is 3.5-5.0 mmol/L)
4. Requirement for a low potassium enteral formula to provide a minimum of 20% of daily energy (kcal) requirements. (calculated according to individual child's needs and according to local clinical practice)
5. Written informed consent provided by parent/primary caregiver.
6. Assent provided by child, if appropriate.

Exclusion Criteria:

1. Receiving total parenteral nutrition (TPN).
2. Intolerance or allergy to cow's milk or any other ingredients in Renastart.
3. Prior intolerance of Renastart formula.
4. Any disorders which in the investigator's opinion may cause significant gastrointestinal malabsorption.
5. Liver failure.
6. Active infection or presenting with any signs or symptoms of an infectious disease at screening.
7. Concurrent enrollment into another clinical trial.
Interactive Tablet Compared to Oral Midazolam as Premedication in Preoperative Anxiety in Children

preoperative anxiety is an undesirable outcome in pediatric surgical patients.It can lead to behavioral trouble such as enuresis, apathy and sleep disorders.

to prevent this anxiety,many tools can be used for premedication like pharmacological:Midazolam, clonidine, hydroxysine or non pharmacological tools such as parental presence,hypnosis and interactive tablet.

the purpose of the study is to compare the effect of interactive tablet to oral midazolam.on preoperative anxiety in children prior to elective surgery

this study is a prospective,randomized, active treatment controlled trial.It enrolls 100 children .

after written and informed consent,the study participants were randomly assigned using a computer generated table to one of two treatment groups prior to elective surgery.

Group T: will receive an interactive tablet containing many cartoon's videos 20 minutes before the parental separation and until the anesthesia induction Group MD:will receive oral midazolam 20 minutes before parental separation with 0.5 mg/kg (max 20mg) Anxiety assessement was done using the Modified Yale Perioperative Anxiety Scale( MYPAS) at the separation of parents,the admission in the operating room and the anesthesia induction.

Facial mask acceptance,post operative agitation (PAEDS score: Pediatric Anesthesia Emergence of Delirium) and parental satisfaction were also assessed.

Eligibility Criteria:
Inclusion Criteria:

* 3-10 years old children
* elective surgery
* ASA PS I/II

Exclusion Criteria:

* Parental refusal
* Emergency procedure
* Behavioral or psychiatric disorders
* allergy or hypersensitivity to midazolam
Genetics of Spina Bifida and Anencephaly

The goal of this research study is to discover the genetic and environmental factors that contribute to the cause of neural tube defects such as spina bifida and anencephaly. Ultimately, this type of research may result in improved diagnosis, improved treatment and possibly prevention.


Eligibility Criteria:
Not currently enrolling new participants.
Patient Centered-Rehabilitation ver111090.1

As we age, a number of factors can reduce our cognitive (or thinking) abilities. This study will evaluate whether transcranial electrical stimulation (TES), which uses small amounts of electricity to modulate brain functioning, can improve cognitive abilities. Here, the effects of TES on working memory, learning, and memory, will be evaluated in a group of healthy older adults.

The primary objective is to investigate the cognitive effects of high definition anodal tDCS (HD-tDCS; anode at center electrode) at 3 mA (for 20 minutes) on learning, memory, and working memory. Participants will be randomized to active or sham stimulation and will complete a series of cognitive tests both during and after stimulation.

Tolerability and blinding will also be evaluated using standard side effect questionnaires.

Eligibility Criteria:
Inclusion Criteria:

1. Individuals with intact cognitive functioning.
2. Participants will be age 50 or older.

Exclusion Criteria:

1. Individuals with a documented history of cognitive impairment.
2. A history of serious mental illness (e.g., bipolar disorder, schizophrenia, axis 2 disorders)
3. Sensory or motor impairments that limit the ability to take part in the study
4. A significant history or current use of alcohol or drug abuse/dependence
5. Those who are currently pregnant (if there is a question of pregnancy, pregnancy tests will be available for participants at no charge)
6. Participants with an Mini Mental State Examination score \<24 at screening.
Web-Based Fall Prevention Program for Elderly

Fall is one of the most common problems experienced by the elderly, is an important public health problem in many societies. Falls are one of the leading causes of fatal and non-fatal injuries in the elderly. An average of one-third of individuals aged 65 and over have a fall at least once each year. The research will be carried out on the web page that on fall prevention prepared within the scope of this project. The aim of this project is to assess the effect of Web-Based Fall Prevention Program on falling, fall risk and fear of fall.

The research was planned as a experimental design with a pretest- posttest control group design. It will be with individuals over the age of 65. The sample size of the research is consists of 72 people who agreed to participate in the research. Participant will be randomly assigned to the experimental and control groups via computer programı (random.org).

The research will be conduct on a web-based basis.The six-week web-based program includes health education, exercise and safe home environment initiatives.

Eligibility Criteria:
Inclusion Criteria:

* Willing to participate in the study,
* 65 years or older,
* Completing the Timed Up and Go (TUG) test for 12 seconds or more,
* Having internet access and the ability to use communication tools such as computers, tablets or smartphones,
* Not dependent on bed,
* Without moderate and severe cognitive impairment (Mini Mental State Test-MMD ≥24),

Exclusion Criteria:

* Illiterate,
* Visually impaired,
* Physical condition or disease that may prevent exercise (Multiple Sclerosis, Parkinson, with a fracture, artificial knee- hip-joint in the last six months etc..)
Ocular Biometrics in a French Population

The investigators aimed to study ocular biometrics parameters and their association with age, gender and the prevalence of high myopia in a population of cataract surgery candidates in the South of France. The investigators also aimed to define proportion of an "usual eye" and know the rate of inhomogeneous eyes in our population.


Eligibility Criteria:
Inclusion criteria:

* aged 40 years
* olderpatients who underwent ocular biometrics before cataract surgery

Exclusion criteria: incomplete examination

* previous cataract surgery
* age \< 40 years
Optical Coherence Tomography Angiography Examinations in Chronic Retinal Artery Occlusion

Purpose of the study is to examine the retinal blood flow in chronic cases of retinal artery occlusion with non-invasive, non-contact optical coherence tomography angiography.

Occlusion of the retinal arteries is an emergency which causes sudden, painless unilateral vision loss. Loss of blood flow causes ischemic damage to the retina. The extent of damage depends on the area affected.

Following the acute phase of the disease re-canalization occurs and lesser blood flow can be detected usually without functional recovery.

Purpose of the study is to examine the retinal blood flow in chronic cases of retinal artery occlusion.

Standard procedures to examine this disease include retinoscopy following pupil dilation, fluorescein angiography and more recently, optical coherence tomography (OCT).

The latest direction in OCT development was OCT angiography (OCTA) which is a software upgrade that allows detection of blood flow based on motion contrast. Similar to previous OCT machines OCTA is also non-invasive and non-contact and does not require any intravenous agents.

OCT machines are approved in the EU and the US and are not experimental devices.

The device used in this study is the commercially available Zeiss Cirrus HD OCT Angioplex 5000 that operates with spectral-domain technology.

Eligibility Criteria:
Inclusion Criteria:

* central or branch retinal artery occlusion
* at least 6 months of onset
* signed informed consent

Exclusion Criteria:

* known epilepsy
* incapacity
* presence of optical media opacities that would disturb the imaging
* presence of other retinal diseases that would disturb the evaluation of images
Measurement of Cardiac Output in Intensive Care Unit With Unstable Hemodynamic: Validation of Physioflow® Device Versus Trans Thoracic Echocardiography

Physioflow® is a new device for measuring cardiac output in a non-invasive way using a thoracic bioimpedance technique. This technique has been validated in patients in stress tests as well as in Chronic Obstructive Pulmonary Disease (COPD) patients, in obese patients and in children. Very little work has been published in intensive care unit (ICU) and no studies have been done on hemodynamically unstable patients. The aim of this work is to compare the cardiac output measured by Physioflow® to the transthoracic echocardiography (TTE) in ventilated, sedated patients hospitalized in ICU receiving catecholamines and for whom the attending physician wants to evaluate the fluid responsiveness using the TTE and a passive leg raising maneuver (PLR).

All patients included will be simultaneously monitored with TTE and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after PLR. If the attending physician decide to administer fluid expansion a new set of cardiac output measurement will be performed before and after the volume expansion.

Eligibility Criteria:
Inclusion Criteria:

* patient more than 18 year-old
* patient sedated and adapted to the assisted controlled ventilation
* patient receiving catecholamine (norepinephrine, epinephrine or dobutamine)
* patient requiring an haemodynamic evaluation by trans-thoracic echocardiography and PLR according to the attending physician

Exclusion Criteria:

* pregnant women
* patients with a poor echogenicity
* patients deprived of public law
Laparoscopic Sleeve Gastrectomy Under General Anesthesia in Severely Obese Patients: a Retrospective Study

With the improvement of living standards and changes in living habits in China, obesity has become an important issue. The latest data show that the number of obese people in China has exceeded 100 million. Laparoscopic sleeve gastrectomy (LSG), which reduces the volume of the stomach and maintains the original anatomical structure of the gastrointestinal tract, has been widely used in weight loss surgery for obese patients to improve glucose metabolism and other metabolic disease comorbidities.Anesthesiologists face specific challenges for obese patients: difficult venous and airway access and the risk of obesity-related comorbidity.

Since 2015, the investigator's center has performed LSG and gradually formed a multidisciplinary collaboration procedure for the perioperative management of obese patients. This study aims to summarize the clinical characteristics, anesthesia management and outcomes to optimize the perioperative management and accelerate the recovery of these patients.


Eligibility Criteria:
Inclusion Criteria:

1. patients aged\>18 years
2. American Society of Anesthesiologists (ASA) status I-III
3. receiving selective laparoscopic sleeve gastrectomy (LSG) under general anesthesia

Exclusion Criteria:

1.BMI\<35 kg/m2
Treating Bacterial Overgrowth in Parkinson's Disease

This study investigates the effect of treating Small Intestinal Bacterial Overgrowth (SIBO) in patients with Parkinson's Disease (PD). It will test the hypothesis that treating SIBO with the antibiotic rifaximin will improve motor complications in previously SIBO-positive PD patients.

Parkinson's Disease (PD) patients with motor fluctuations will be screened for the presence of Small Intestinal Bacterial Overgrowth (SIBO) using two hydrogen breath tests. SIBO-positive individuals will be eligible to enroll, and randomized to receive either rifaximin or placebo. This study includes two treatment regimens (including a placebo control), designed so that all patients will receive the active drug at some point during the trial. Motor outcomes will be followed for 3 or 6 months following enrollment, depending on the treatment arm to which the subject has been assigned. The primary endpoint is to assess the effect of rifaximin treatment to decrease "off" time in SIBO-positive PD patients.

This pilot study will support the design of a larger, randomized controlled trial investigating the effect of SIBO eradication on reducing motor complications in PD patients with motor fluctuations. The current proposal is designed to demonstrate our ability to detect and treat SIBO in PD patients with motor fluctuations, to inform selection of the best SIBO detection method, to determine the optimal timeline for assessing motor endpoints, and to estimate the duration of benefits after treatment.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of idiopathic PD
* Daily "off" time ≥ 4 hours
* No changes in levodopa or any other dopaminergic medications expected during the course of the study
* Will be screened for cognitive ability (Montreal Cognitive Assessment score of ≥ 24) prior to enrollment
* Will be screened for presence of SIBO prior to enrollment

Exclusion Criteria:

* Any comorbid non-PD-associated gastrointestinal (e.g., achlorhydria) or systemic diseases that may alter absorption or confound the study results
* Exposure to proton pump inhibitors, immunosuppressive drugs, medications that affect GI motility (such as prokinetics, anticholinergics, and tricyclic antidepressants), antibiotics or any other drugs that affect the intestinal flora (such as laxatives) within a month prior to enrollment.
* Prior deep brain stimulation or ablative functional neurosurgery.
* Prior allergy to rifaximin
* Women who are pregnant, lactating, or plan to become pregnant.
Expanded Access to Burosumab

Individual patient expanded access requests may be considered for patients who have no other treatment options

Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.

Eligibility Criteria:
Inclusion Criteria:

-

Exclusion Criteria:

-
Circadian as A Prognostic Factor For Radiation Response in Cervical Cancer

The study was a Randomized Clinical Trial (RCT) or clinical trial comparing the results of radiation treatment of 2 treatment groups, i.e. subject groups irradiated in the morning and in the afternoon, to check melatonin levels in cervical cancer patients. Since it is known that the function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.


Eligibility Criteria:
Inclusion Criteria:

* cervical cancer patients stage IIB-IIIB (FIGO)
* no previous treatment
* histopathologic examination results of squamous cell carcinoma (SCC)
* KPS \> 70 with levels of Hb \> 10 g%,

Exclusion Criteria:

* Distant metastasis and locally spread to the adjacent healthy tissue (urinary bladder or rectum).